AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23179805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 60
Study 23179805 — intervention group
Group type: COMPARATOR
Intervention: Intracorporeal sutures
Number of subjects: 60
Study 21282590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 167
Study 21282590 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab + Irinotecan (BEV+CPT‐11)
Number of subjects: 167
Study 18454914 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% solution of betadine irrigation before final closing of the wound (Group 1)
Number of subjects: 162
Study 18454914 — intervention group
Group type: COMPARATOR
Intervention: No betadine irrigation during the intraoperative period (Group 2)
Number of subjects: 162
Study 16792606 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% supplemental oxygen
Number of subjects: 560
Study 14599044 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Number of subjects: 0
Study 14599044 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 0
Study 14599044 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture
Number of subjects: 0
Study 10938492 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 298
Study 10938492 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 2.0 mg
Number of subjects: 298
Study 8737690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg orally TID for 3 days preoperatively and 300 mg infusion after anesthetic induction
Number of subjects: 20
Study 8737690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 20
Study 1559860 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 25
Study 1559860 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 25
Study 3933393 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids (BCAA)
Number of subjects: 12
Study 3933393 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% branched chain amino acids (BCAA)
Number of subjects: 12
Study 3933393 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 12
Study 30578542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 12 weeks)
Number of subjects: 56
Study 30578542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30578542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (in black women subgroup)
Number of subjects: 56
Study 30578542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in black women subgroup)
Number of subjects: 56
Study 30578542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (in obese women subgroup)
Number of subjects: 56
Study 30578542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in obese women subgroup)
Number of subjects: 56
Study 30578542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 56
Study 29035099 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 levels in LVH patients (n=67)
Number of subjects: 302
Study 29035099 — intervention group
Group type: COMPARATOR
Intervention: GDF‐15 levels in non-LVH patients (n=172)
Number of subjects: 302
Study 29035099 — intervention group
Group type: COMPARATOR
Intervention: GDF‐15 levels in healthy controls (n=63)
Number of subjects: 302
Study 27283096 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-integrated weight gain prevention intervention (1-credit academic course and online social networking support)
Number of subjects: 441
Study 24509273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (AMG 145) 140 mg every 2 weeks
Number of subjects: 1359
Study 24509273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (AMG 145) 420 mg every 4 weeks
Number of subjects: 1359
Study 24509273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1359
Study 24509273 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab treatment
Number of subjects: 1359
Study 23156204 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 0
Study 19960343 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele carriers
Number of subjects: 243
Study 19960343 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker and ex-smoker individuals
Number of subjects: 243
Study 19960343 — intervention group
Group type: COMPARATOR
Intervention: Non-smoker NSCLC patients
Number of subjects: 243
Study 17298834 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10mg/day)
Number of subjects: 40
Study 17298834 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 15616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 7.5 mg/kg/day
Number of subjects: 54
Study 15616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 12.5 mg/kg/day
Number of subjects: 54
Study 15616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 15 mg/kg/day
Number of subjects: 54
Study 15616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (multiple doses)
Number of subjects: 54
Study 15616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (24 h postinfusion)
Number of subjects: 54
Study 12062586 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of M. officinalis (Pharmaton)
Number of subjects: 20
Study 12062586 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of M. officinalis (Pharmaton)
Number of subjects: 20
Study 12062586 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of M. officinalis (Pharmaton)
Number of subjects: 20
Study 12062586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10652673 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal system
Number of subjects: 0
Study 10652673 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 0
Study 7548608 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cellulose membranes
Number of subjects: 0
Study 7548608 — intervention group
Group type: COMPARATOR
Intervention: Synthetic membrane (polysulphone)
Number of subjects: 0
Study 2303613 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential death education programme
Number of subjects: 0
Study 2303613 — intervention group
Group type: COMPARATOR
Intervention: Didactic or placebo programme
Number of subjects: 0
Study 7385085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette (2.6 mg nicotine, 4.5 vol percent CO)
Number of subjects: 10
Study 7385085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette (0.1 mg nicotine, 1.1 vol percent CO)
Number of subjects: 10
Study 7385085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar (not inhaled)
Number of subjects: 10
Study 7385085 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette after beta blocker
Number of subjects: 10
Study 7385085 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of CO
Number of subjects: 10
Study 31187239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tragal cartilage perichondrium graft (Group A)
Number of subjects: 35
Study 31187239 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal muscle fascia graft (Group B)
Number of subjects: 35
Study 28287024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT) 3 times/week for 24 weeks
Number of subjects: 22
Study 28287024 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 26296853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFEs)
Number of subjects: 162
Study 26296853 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Amplification (VA)
Number of subjects: 162
Study 26296853 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 162
Study 23498294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight‐loss program (LWL)
Number of subjects: 301
Study 23498294 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care condition (UCC)
Number of subjects: 301
Study 22070180 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (n=40)
Number of subjects: 21
Study 22070180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=37)
Number of subjects: 21
Study 22070180 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-free subjects with autism (n=77)
Number of subjects: 21
Study 18442947 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive physiological movements (PPMs) for 30 min using an electrically driven bicycle
Number of subjects: 17
Study 18442947 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive physiological movements (PPMs)
Number of subjects: 17
Study 18442947 — intervention group
Group type: COMPARATOR
Intervention: Control (no PPM)
Number of subjects: 17
Study 17566190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 12
Study 17566190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 12
Study 17566190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alcohol)
Number of subjects: 12
Study 12351525 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 48
Study 12351525 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH + recombinant LH (rLH)
Number of subjects: 48
Study 10825870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light‐cured composite materials
Number of subjects: 130
Study 7565419 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. propofol 2.5 mg/kg (G1, G3, G5)
Number of subjects: 72
Study 7565419 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg (G2, G4, G6)
Number of subjects: 72
Study 7565419 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg (G1, G2)
Number of subjects: 72
Study 7565419 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg (G3, G4)
Number of subjects: 72
Study 7565419 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg followed by propofol or thiopental (G5, G6)
Number of subjects: 72
Study 7565419 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1-G6)
Number of subjects: 72
Study 2405779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranimustine
Number of subjects: 77
Study 2405779 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 77
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium containing 53 mg iodine/kg body weight
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium containing 75 mg iodine/kg body weight
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium containing 106 mg iodine/kg body weight
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium containing 150 mg iodine/kg body weight
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion technique over 3-8 hours
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage regimen (106 mg and 150 mg iodine/kg)
Number of subjects: 102
Study 465920 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of IVC
Number of subjects: 102
Study 31136582 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC+EVR
Number of subjects: 40
Study 31136582 — intervention group
Group type: COMPARATOR
Intervention: TAC+MMF
Number of subjects: 40
Study 28230784 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Grains (WG)
Number of subjects: 0
Study 28230784 — intervention group
Group type: COMPARATOR
Intervention: Refined Grains (RG)
Number of subjects: 0
Study 25559090 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based memory rehabilitation programme (10 weekly sessions)
Number of subjects: 312
Study 25559090 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study 23667649 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 66
Study 23667649 — intervention group
Group type: COMPARATOR
Intervention: Overweight women
Number of subjects: 66
Study 21832026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (52.25 μmol)
Number of subjects: 500
Study 21832026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 19298097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vermedx Diabetes Information System (DIS)
Number of subjects: 1023
Study 19298097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1023
Study 17512355 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin and statin-ezetimibe interventions
Number of subjects: 57
Study 17512355 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day of statins
Number of subjects: 57
Study 17512355 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL lowering
Number of subjects: 57
Study 17512355 — intervention group
Group type: COMPARATOR
Intervention: Statin therapies
Number of subjects: 57
Study 17512355 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL reduction (20% to 60%)
Number of subjects: 57
Study 15161680 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (80 microg/day for 4 consecutive days) at each immunization
Number of subjects: 24
Study 15161680 — intervention group
Group type: COMPARATOR
Intervention: Recombinant CEA alone
Number of subjects: 24
Study 15161680 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 24
Study 15161680 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEA IgG titers
Number of subjects: 24
Study 11297894 — intervention group
Group type: EXPERIMENTAL
Intervention: Stamped return envelopes
Number of subjects: 3000
Study 11297894 — intervention group
Group type: COMPARATOR
Intervention: Business reply envelopes
Number of subjects: 3000
Study 11297894 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of response rates
Number of subjects: 3000
Study 9495264 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP (2 pmol/kg per minute for 1 hour)
Number of subjects: 6
Study 9495264 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP (4 pmol/kg per minute for 1 hour)
Number of subjects: 6
Study 9495264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7980076 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg
Number of subjects: 40
Study 7980076 — intervention group
Group type: COMPARATOR
Intervention: nifedipine retard 20 mg
Number of subjects: 40
Study 2647192 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.12% mouth rinse
Number of subjects: 100
Study 2647192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31791665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 44
Study 31791665 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 44
Study 29318421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team assessment and multimodal intervention (TEAM)
Number of subjects: 401
Study 29318421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 401
Study 29318421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 401
Study 28216842 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 45
Study 25673574 — intervention group
Group type: EXPERIMENTAL
Intervention: PHA/BI plus CO
Number of subjects: 185
Study 25673574 — intervention group
Group type: COMPARATOR
Intervention: CO only
Number of subjects: 185
Study 25673574 — intervention group
Group type: COMPARATOR
Intervention: PHA/BI only
Number of subjects: 185
Study 25673574 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 185
Study 22102140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain expectation
Number of subjects: 0
Study 22102140 — intervention group
Group type: COMPARATOR
Intervention: Placebo-analgesia expectation
Number of subjects: 0
Study 21045724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 24
Study 21045724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 24
Study 21045724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18584971 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame smoking cessation message emphasizing benefits of quitting
Number of subjects: 151
Study 18584971 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative frame smoking cessation message emphasizing costs of not quitting
Number of subjects: 151
Study 15465618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose
Number of subjects: 0
Study 15465618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11261828 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 11261828 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 11261828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 9676471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenoxicam 40 mg
Number of subjects: 25
Study 9676471 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tenoxicam 40 mg
Number of subjects: 25
Study 7833497 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide, 80 mg twice daily for 5 weeks
Number of subjects: 0
Study 7833497 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at 50 microU/mL
Number of subjects: 0
Study 7833497 — intervention group
Group type: COMPARATOR
Intervention: Insulin at 5 microU/mL
Number of subjects: 0
Study 7833497 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide treatment
Number of subjects: 0
Study 3056045 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic polymer insole
Number of subjects: 3025
Study 3056045 — intervention group
Group type: COMPARATOR
Intervention: Standard mesh insole
Number of subjects: 3025
Study 3056045 — intervention group
Group type: COMPARATOR
Intervention: Age of shoes
Number of subjects: 3025
Study 3056045 — intervention group
Group type: COMPARATOR
Intervention: History of physical activity
Number of subjects: 3025
Study 3056045 — intervention group
Group type: COMPARATOR
Intervention: Racial background (White vs Black recruits)
Number of subjects: 3025
Study 31079243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival ultrasonic debridement with low-concentrated hypochlorite/amino acid gel
Number of subjects: 32
Study 31079243 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic debridement only
Number of subjects: 32
Study 30360969 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for 16 weeks
Number of subjects: 131
Study 30360969 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once daily for 16 weeks
Number of subjects: 131
Study 30360969 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 131
Study 30360969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 27544583 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition (Ex + N)
Number of subjects: 139
Study 27544583 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (Ex)
Number of subjects: 139
Study 27544583 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 139
Study 24374088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 50
Study 24374088 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 21761263 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexperimental inquiries (PEI) administered as a computer survey with a reward offered
Number of subjects: 0
Study 21761263 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexperimental inquiries (PEI) administered as a face-to-face interview
Number of subjects: 0
Study 21761263 — intervention group
Group type: COMPARATOR
Intervention: Postexperimental inquiries (PEI) without any specific intervention
Number of subjects: 0
Study 20670666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat drink
Number of subjects: 24
Study 20670666 — intervention group
Group type: COMPARATOR
Intervention: High-fat drink with orlistat
Number of subjects: 24
Study 20670666 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 20670666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drink
Number of subjects: 24
Study 20670666 — intervention group
Group type: COMPARATOR
Intervention: Sucrose drink with acarbose
Number of subjects: 24
Study 18571267 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% anaerobic threshold (AT)
Number of subjects: 11
Study 18571267 — intervention group
Group type: EXPERIMENTAL
Intervention: 110% anaerobic threshold (AT)
Number of subjects: 11
Study 18571267 — intervention group
Group type: COMPARATOR
Intervention: Control session (CON)
Number of subjects: 11
Study 15965424 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week alefacept treatment
Number of subjects: 20
Study 15965424 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week alefacept treatment
Number of subjects: 20
Study 11490696 — intervention group
Group type: EXPERIMENTAL
Intervention: Small access incision with minimal reflection of the mucoperiosteum
Number of subjects: 20
Study 11490696 — intervention group
Group type: COMPARATOR
Intervention: Standard mucoperiosteal flap
Number of subjects: 20
Study 9924833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation-retreat model intervention
Number of subjects: 97
Study 9924833 — intervention group
Group type: COMPARATOR
Intervention: Control unit care
Number of subjects: 97
Study 8067226 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated equipment (CBAS) with reduced i.v. heparin (1.5 mg.kg‐1)
Number of subjects: 20